An Unexpected Metabolite Reveals a New Weakness in Ependymomas
Ependymomas are rare tumors of the brain or spinal cord that affect both children and adults. Supported by a 2025 AACR-Sontag Foundation Brain Cancer Research Fellowship, research conducted by Siva Kumar Natarajan, PhD, identified itaconate, a metabolite more commonly associated with immune responses, as a previously unrecognized driver of ZFTA-RELA+ ependymomas. The study also uncovered metabolic vulnerabilities with therapeutic potential against these aggressive tumors.
